Danish drugmaker LEO Pharma postpones its stock market listing
Published
The Danish pharmaceutical company LEO Pharma is putting its plans for a stock market listing (IPO) on hold. The company will not go public for the time being. According to the reports, there will be no listing in 2026.
LEO Pharma is one of the larger pharmaceutical companies in Denmark. The company develops and sells medicines, mainly for skin diseases. Going public means that a company sells shares to the general public. This often brings in capital, but it also requires the company to open its business to investors and to be closely followed by the market.
It is not unusual for companies to postpone stock market listings when the market situation is uncertain. Investors may be cautious, and the valuation of companies may end up lower than the companies hoped. There are not yet any detailed details about the reasons LEO Pharma has given for the decision.
For Swedish readers, the news is mainly interesting because it concerns a Nordic pharmaceutical company and shows how conditions in the capital market can affect large companies in the region. It is still unclear when LEO Pharma may resume its plans. So far, the company has only said that there will be no stock market listing this year.
Sources: lifesciencefocus.com
More Sweden news
- Slow start for Sverige-id: authorities can get up to nine months' exemption
- Marcus Bergman leaves Sweden after more than 400 matches in Hockeyallsvenskan
- Trust in Sweden could affect the country's defence capability
- New rabies vaccine from Sanofi approved in the EU
- This is what the Swedish royals are really like, according to an expert
- Musikhjälpen 2026: The first prize is tickets to a Premier League match
- Business leaders impatient with AI: small progress is no longer enough
- Sweden expected to attract twice as much venture capital this year